• 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Please login or register to take this course.
Program Description: 

 
 

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Medical College of Wisconsin and International Society on Thrombosis and Haemostasis. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
 
Designation of Credit Statement:
The Medical College of Wisconsin designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Please note: The course fee is $10.00 in addition to a $2.50 processing fee which is assessed for all electronic registrations.
 
More information and online registration:  http://academy.isth.org/isth/ 
 
 
This course is being supported by Instrumentation Laboratory
Target audience: 
Physicians of all disciplines involved in the care of patients with acute pulmonary embolism: Cardiologists, Pulmonologists, Hematologists, Hemostaseologists, Internists, Anesthesiologists, Intensivists, Cardiothoracic Surgeons
Learning objectives: 

At the conclusion of this activity, I will be able to:

  • Understand the global disease burden related to venous thromboembolism
  • Apply evidence-based, risk-adjusted algorithms to diagnose or exclude clinically suspected pulmonary embolism
  • Distinguish between intermediate-high, intermediate-low, and low-risk pulmonary embolism, and apply this knowledge in the acute-phase management
  • Understand the modalities, benefits, indications and caveats of early reperfusion therapy: systemic full-dose thrombolysis, reduced-dose thrombolysis, surgical embolectomy, or catheter-directed treatment
  • Decide on the use vitamin K antagonists versus non-vitamin K-dependent oral anticoagulants (NOACs) in the treatment and secondary prophylaxis of PE, in relation to lytic or other reperfusion therapy
Faculty & credentials: 
Planning Committee:
Geoffrey Barnes, MD
Chris Ward, PhD
Stephen Watson, PhD
Yukio Ozaki
 
Speakers:
Stavros Konstantinides, Johannes Gutenberg University of Mainz (Germany)
 
Moderator:  

Raj Kasthuri, University of North Carolina (USA)

All persons in control of content have NO relevant financial relationships to disclose with the exception of the following persons:  
 

Name

Company

Role

Geoffrey Barnes, MDPortolaConsulting
 Blue Cross Blue Shield of MichiganResearch
 BMS/PfizerResearch
Chris Ward, PhDBayerSpeaker
 Boehringer-IngelheimSpeaker, Advisory Board
 BMS/PfizerSpeaker, Advisory Board
   
Yukio OzakiThe Sysmex CorporationAdvisory Board
Stavros KonstantinidesDaiichi SankyoSpeaker
 Bayer HealthcareSpeaker
 Boehringer IngelheimSpeaker
 Pfizer-BMSSpeaker
Raj KasthuriBayer HealthcareConsultant
 GSKConsultant

In accordance with the ACCME®  Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved.

CME Coordinator Contact Information

Name: 
Lacey Schmeidler, MA
Phone number: 
+1 (919) 929-3807